Warfarin Anticoagulation in Patients in Sub-Saharan Africa

Plain-language summary

This study examines the response to anticoagulation (blood-thinning treatment) in patients taking the blood thinner Warfarin in Sub-Saharan Africa. It enrolled patients over 18 of self-reported Black African ethnicity who were taking Warfarin for venous thromboembolism, atrial fibrillation, or valvular heart disease. This was a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University of Liverpool

Start date

6/11/2018

Estimated completion

7/29/2024

Countries

South Africa, Uganda

Related genes

Locations

• Cape Town, South Africa
• Kampala, Uganda

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Consenting adult patients with either venous thromboembolism (VTE), atrial fibrillation (AF) on warfarin with a target International Normalised Ratio (INR) (INR range 2-3) or valvular heart disease with a target INR (INR range 3-4).
2. On a stable maintenance dose for two consecutive clinic visits within the last six months, and the INR was in the therapeutic range at each of those visits.
3. Age over 18 years.
4. Self-reported Black African ethnicity.
5. Signed or witnessed written (witnessed thumbprint for illiterate participants) informed consent.

Exclusion Criteria:

1. Patient unwilling to take part.
2. Patient is, in the opinion of the investigator, not suitable to participate.
3. Pregnant women.